文献速递系统性红斑狼疮

利用B细胞生物标志物预测和管理系统性红斑狼疮患者对利妥昔单抗的原发性和继发性无应答

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
PubMed 文献 · Ann Rheum Dis · 2017-07-06

该前瞻性研究纳入125例接受利妥昔单抗治疗的SLE患者,评估原发性和继发性无应答的相关因素及继发性非耗竭性无应答(2NDNR)的管理。研究发现,年轻和6周时B细胞耗竭与主要临床应答相关;2NDNR与抗利妥昔单抗抗体相关,换用人源化抗CD20药物可恢复耗竭和应答。

要点

  • 年轻和6周时B细胞耗竭增加主要应答几率
  • 2NDNR发生率为12%,与抗利妥昔单抗抗体相关
  • 换用奥瑞珠单抗或奥法木单抗可恢复B细胞耗竭和应答

核心结论

  • 抗CD20治疗可通过B细胞监测指导,应追求完全耗竭。
  • 2NDNR与抗利妥昔单抗抗体相关,换用人源化药物可恢复耗竭和应答。
  • 在SLE中,替代抗CD20抗体可能更持续有效。

研究设计与样本

  • 前瞻性研究,纳入125例接受利妥昔单抗治疗的SLE患者,历时12年。
  • 主要临床应答定义为所有活动性BILAG-2004域改善至C级或更好且无A/B flare。
  • 部分应答定义为持续一个BILAG B。
  • 使用高敏感流式细胞术测量B细胞亚群。
  • 2NDNR定义为输注反应和耗竭缺陷,患者换用奥瑞珠单抗或奥法木单抗。

主要发现

  • 117例有可评估数据,第一周期96/117(82%)达到BILAG应答(主要=50%,部分=32%)。
  • 多变量分析中,年轻(OR 0.97,95%CI 0.94至1.00)和6周时B细胞耗竭(OR 3.22,95%CI 1.24至8.33)增加主要应答的几率。
  • 完全耗竭由正常补体和较低利妥昔单抗前浆细胞预测,且与利妥昔单抗后严重感染增加无关。
  • 72例第一周期应答者中有61/72(85%)在第二周期应答;11例第二周期无应答者中9例符合2NDNR标准(发生率=12%)且抗利妥昔单抗抗体阳性。
  • 缺乏伴随免疫抑制剂和较高利妥昔单抗前浆细胞预测2NDNR;5例换用奥瑞珠单抗/奥法木单抗后均耗竭并应答。

关键数值与推荐

  • 主要临床应答:所有活动性BILAG-2004域改善至C级或更好且无A/B flare。
  • 部分应答:持续一个BILAG B。
  • 2NDNR:输注反应和耗竭缺陷。
  • 2NDNR发生率=12%。

临床怎么用

  • 治疗抗CD20药物时应通过B细胞监测指导,并追求完全耗竭。
  • 对于2NDNR患者,可换用人源化抗CD20药物如奥瑞珠单抗或奥法木单抗。
  • 缺乏伴随免疫抑制剂和较高利妥昔单抗前浆细胞提示2NDNR风险,需关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess factors associated with primary and secondary non-response to rituximab in systemic lupus erythematosus (SLE) and evaluate management of secondary non-depletion non-response (2NDNR). METHODS: 125 patients with SLE treated with rituximab over 12 years were studied prospectively. A major clinical response was defined as improvement of all active British Isles Lupus Assessment Group (BILAG)-2004 domains to grade C/better and no A/B flare. Partial responders were defined by one persistent BILAG B. B-cell subsets were measured using highly sensitive flow cytometry. Patients with 2NDNR, defined by infusion reaction and defective depletion, were treated with ocrelizumab or ofatumumab. RESULTS: 117 patients had evaluable data. In cycle 1 (C1), 96/117 (82%) achieved BILAG response (major=50%, partial=32%). In multivariable analysis, younger age (OR 0.97, 95% CI 0.94 to 1.00) and B-cell depletion at 6 weeks (OR 3.22, 95% CI 1.24 to 8.33) increased the odds of major response. Complete depletion was predicted by normal complement and lower pre-rituximab plasmablasts and was not associated with increased serious infection post-rituximab. Seventy-seven (with data on 72) C1 responders were retreated on clinical relapse. Of these, 61/72 (85%) responded in cycle 2 (C2). Of the 11 C2 non-responders, nine met 2NDNR criteria (incidence=12%) and tested positive for anti-rituximab antibodies. Lack of concomitant immunosuppressant and higher pre-rituximab plasmablasts predicted 2NDNR. Five were switched to ocrelizumab/ofatumumab, and all depleted and responded. CONCLUSION: Treatment with anti-CD20 agents can be guided by B-cell monitoring and should aim to achieve complete depletion. 2NDNR is associated with anti-rituximab antibodies, and switching to humanised agents restores depletion and response. In SLE, alternative anti-CD20 antibodies may be more consistently effective.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Md Yusof MY, Shaw D, El-Sherbiny YM, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017. PMID: 28684557. doi:10.1136/annrheumdis-2017-211191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。